Pharsight

Temodar generic

Temodar is an anti-cancer drug owned by Merck Sharp Dohme. The active ingredient in this drug is temozolomide. It was first authorized for market use on 27th February, 2009. The drug has been patented 3 times, with all 3 patents now expired.

When will Temodar generic be available?

The generic version of Temodar could have been released after the expiry of its last patent on 8th September, 2023. However, all patents for this drug are now expired, making the release of Temodar generic quite possible.

Temodar uses

Temodar is used in the treatment of cancer. The active ingredient, temozolomide, works by damaging the DNA in the cancer cells and stopping their growth. This drug is available in the form of a powder for intravenous administration.

Temodar patent expiration

Temodar has held a total of three patents, all of which have now expired. The last patent was titled 'Pharmaceutical formulations of antineoplastic agents and processes of making and using the same' (US6987108), and it expired on 8th September, 2023. Below are the details of the patent:

EPO Oppostions filed on Temodar

Temodar dosage

Want to ask something?